BRIEF—Elasmogen and ImmunoForge agree licensing deal

Elasmogen and ImmunoForge, a firm focusing on sarcopenia and cancer, have agreed a license agreement whereby Elasmogen’s proprietary NDure half-life extension technology will be used for two non-disclosed targets.

ImmunoForge will be responsible for all pre-clinical and clinical development, manufacturing and commercialisation, and will make an undisclosed upfront payment as well as milestone and royalty payments.

Elasmogen chief executive Caroline Barelle said: “This licensing agreement provides further validation of the benefits of our soloMER platform and NDure technology. At less than 1/10th the size of an antibody, NDure allows rapid re-formatting and simple manufacturing while retaining all of the benefits of high specificity albumin binding.”